Drug Type Protein drugs |
Synonyms NEO-2/15 (Neoleukin Therapeutics), NL 201(Neoleukin Therapeutics), NL-201(Neoleukin Therapeutics) |
Target |
Mechanism IL-15 modulators(Interleukin-15 modulators), IL-2Rβγ agonists(Interleukin-2 Rβγ agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | Neurogene, Inc. (New York)Startup | 26 Apr 2021 |
Advanced Malignant Solid Neoplasm | Phase 1 | AU | Neurogene, Inc. (New York)Startup | 26 Apr 2021 |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | Neurogene, Inc. (New York)Startup | 26 Apr 2021 |
Recurrent Carcinoma | Phase 1 | US | Neurogene, Inc. (New York)Startup | 26 Apr 2021 |
Recurrent Carcinoma | Phase 1 | AU | Neurogene, Inc. (New York)Startup | 26 Apr 2021 |
Recurrent Carcinoma | Phase 1 | CA | Neurogene, Inc. (New York)Startup | 26 Apr 2021 |